BioPulse Announces Angiogenesis Cancer Treatment

August 16, 2000

SOUTH JORDAN, Utah, Aug. 16 /PRNewswire/ -- BioPulse International, Inc. (OTC Bulletin Board: BIOP - news) today announced the acquisition of the exclusive intellectual property rights to PGM, a patented anti-angiogenesis product. BioPulse-affiliated clinics will immediately begin studying the effects of PGM on the disease processes of people suffering from various cancers including metastatic breast, colon, prostate, stomach, esophagus and lung carcinomas, medulloblastoma, neuroblastoma, mesothelioma, and certain sarcomas.

The growth of new blood vessels is called angiogenesis. Regulation of angiogenesis is a promising area of cancer research because it holds the prospect of a natural, nonsurgical treatment for cancer without the serious side effects of chemotherapy and radiation.

Treatments that inhibit angiogenesis are intended to shut off the blood source that feeds tumors, killing them, or at least halting their growth, while leaving the rest of the body unharmed. A successful anti-angiogenesis treatment would make cancer a manageable disease.

``A tumor is like a wild animal running amok inside the body,'' says Loran Swensen, Director of Clinical Development for BioPulse. ``With PGM, we hope to capture the wild animal, put it in a cage, and hold it there safely while we use other treatments to kill it off. Just preventing the tumor from growing new blood vessels may be enough in some cases to kill the tumor, but if not, we will use other treatments to do this while the PGM holds the tumor in place.''

There are several biotech companies hunting for angiogenesis regulators, including Genentech, ImClone, Bristol-Myers Squibb, EntreMed, and Cellgene. Some of these are already in FDA trials, which have received widespread publicity. PGM has not yet been entered into FDA trials for clinical use in the United States, but the company has plans to do so. PGM was extensively tested by the Biocommunications Research Institute, the developer of the product. Animal trials have shown that PGM significantly inhibits tumor growth in mice. Animal toxicity studies showed PGM to have a very low toxicity and no toxicity at concentrations that inhibited tumor growth. BioPulse licensed the product from Aidan, Incorporated of Tempe, Arizona.

PGM is extracted from a plant. Some experts are skeptical that a plant extract can provide the same benefit as the multi-million dollar pharmaceutical drugs. ``BioPulse focuses on natural remedies and treatments that are considered 'alternative' in the United States, although many of them are used elsewhere in the world as ordinary treatments,'' says Mr. Swensen. ``One of our principal objectives has been to find safe and effective treatments that do not have the harsh side effects of many chemotherapy and radiation treatments common in the United States. PGM fits this model perfectly.''

Clinical applications of PGM are available now at BioPulse-affiliated clinics in Mexico. BioPulse reports that cancer patients with cancer of the esophagus, breast, and colon have responded well to PGM in combination with other BioPulse treatments.

BioPulse International, Inc. (www.biopulse.com) identifies qualified clinics outside the United States and provides management and referral services to make it easier for people to find alternative and advanced treatments for cancer, chronic fatigue, and other health problems. The most advanced cancer treatments are not generally available to Americans until after many years of clinical trials. Many countries outside the United States provide opportunities for their citizens to try innovative treatments, provided the patients are fully informed of the risks and the attending physician is properly licensed. BioPulse-affiliated clinics offer these patients an option to traditional chemotherapy and radiation treatment.

*** POSTED AUGUST 20, 2000 ***